Christina Henson, MD, discusses unmet needs among patients with head and neck cancer.
Christina Henson, MD, radiation oncologist at The University of Oklahoma, discusses unmet needs among patients with head and neck cancer. Here, she discusses studies investigating how to best customize treatment for these patients, especially regarding deescalating treatment to avoid unnecessary toxicities.
Transcription:
0:05 | So far, we haven't found the kind of magic solution or the best way to deescalate on a large scale, but there have been a lot of really promising smaller studies selecting more niche groups of patients either with advanced imaging modalities that aren't necessarily available everywhere but that are able to kind of measure the tumor biology during the course of treatment and use that to determine who's having a good response and who's not having a good response and have the option to stop treatment earlier at lower doses for patients who are responding well.
0:45 | So everyone's hopeful that some time in the near future one of or more than one of is these studies will pan out in a widely applicable way that will be very beneficial for our patients.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More